Published in Am J Cardiol on November 01, 1985
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med (1996) 12.77
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med (1992) 8.38
Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med (1984) 6.74
Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med (1986) 6.58
Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med (2001) 5.30
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med (2001) 3.44
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation (1996) 3.14
Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V Consensus Guidelines. Am J Hypertens (1994) 2.91
Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol (2001) 2.75
Impaired chronotropic response to exercise stress testing as a predictor of mortality. JAMA (1999) 2.74
HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology (1999) 2.49
Cocaine and chest pain: clinical features and outcome of patients hospitalized to rule out myocardial infarction. Ann Intern Med (1991) 2.45
Right ventricular infarction. Clinical and hemodynamic features. Am J Cardiol (1974) 2.30
Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol (1983) 2.24
Improved left ventricular function during nitroprusside infusion in acute myocardial infarction. Lancet (1972) 2.24
Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med (1985) 2.22
Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol (1993) 2.15
Decreased SLIM1 expression and increased gelsolin expression in failing human hearts measured by high-density oligonucleotide arrays. Circulation (2000) 2.04
Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail (1999) 1.96
Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol (2001) 1.91
Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol (1982) 1.91
Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure. Circulation (1980) 1.88
Age-related abnormalities in arterial compliance identified by pressure pulse contour analysis: aging and arterial compliance. Hypertension (1999) 1.86
Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol (1983) 1.80
Treatment of refractory heart failure with infusion of nitroprusside. N Engl J Med (1974) 1.78
Vasodilator therapy for heart failure. The influence of impedance on left ventricular performance. Circulation (1973) 1.78
Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation (1978) 1.77
Vasodilator therapy of cardiac failure: (first of two parts). N Engl J Med (1977) 1.74
Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain (1998) 1.71
Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain (1998) 1.68
Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume expansion. J Clin Invest (1967) 1.67
The neurohumoral axis in congestive heart failure. Ann Intern Med (1984) 1.66
Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol (1995) 1.65
Maximal exercise tolerance as a therapeutic end point in heart failure--are we relying on the right measure? Am J Cardiol (1994) 1.64
Rapid, accurate and simultaneous noninvasive assessment of right and left ventricular mass with nuclear magnetic resonance imaging using the snapshot gradient method. J Am Coll Cardiol (1992) 1.64
Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J (1998) 1.59
ACE inhibition in cardiovascular disease. N Engl J Med (2000) 1.58
Cardiac troponins and chronic kidney disease. Kidney Int (2006) 1.57
Relationship of exercise capacity to resting left ventricular performance and basal plasma norepinephrine levels in patients with congestive heart failure. Am Heart J (1982) 1.57
Noninvasive evaluation of cardiac function in hypothyroidism. Response to gradual thyroxine replacement. N Engl J Med (1977) 1.55
Use of the Living With Heart Failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death. J Card Fail (1995) 1.52
HLA-DQA1 and -DQB1 associations with multiple sclerosis in Sardinia and French Canada: evidence for immunogenetically distinct patient groups. Neurology (1993) 1.52
Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol (1996) 1.51
Vasodilator therapy of cardiac failure (second of two parts). N Engl J Med (1977) 1.50
Neurohumoral control mechanisms in congestive heart failure. Am Heart J (1981) 1.47
Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation (1993) 1.42
Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation (1993) 1.41
HTLV-1 associated myelopathy in Canada. Can J Neurol Sci (1989) 1.40
Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo. Am Heart J (1982) 1.39
The fallacy of the mean. J Card Fail (2001) 1.39
A statistical survey of adverse reactions to LSD in Los Angeles County. Am J Psychiatry (1968) 1.39
Model-based 3-D segmentation of multiple sclerosis lesions in magnetic resonance brain images. IEEE Trans Med Imaging (1995) 1.39
First- and third-order models for determining arterial compliance. J Hypertens Suppl (1992) 1.38
Nitrate therapy for congestive heart failure. JAMA (1978) 1.37
Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. Am J Med (1980) 1.37
Systemic alpha-interferon therapy of multiple sclerosis. Neurology (1984) 1.35
Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology (2005) 1.34
Vascular compliance and cardiovascular disease: a risk factor or a marker? Am J Hypertens (1997) 1.34
Sustained hemodynamic effects without tolerance during long-term isosorbide dinitrate treatment of chronic left ventricular failure. Am J Cardiol (1980) 1.29
Regional differences in adrenergic function within the left ventricle. Am J Physiol (1984) 1.28
Effect of isosorbide dinitrate on response to submaximal and maximal exercise in patients with congestive heart failure. Am J Cardiol (1979) 1.27
Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. Circulation (1995) 1.26
Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects. Circulation (1977) 1.24
Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol (1992) 1.24
Quantitation of portasystemic shunting from the splenic and mesenteric beds in alcoholic liver disease. Am J Med (1972) 1.22
Response of plasma norepinephrine and epinephrine to dynamic exercise in patients with congestive heart failure. Am J Cardiol (1982) 1.20
Relationship between C-reactive protein and arterial stiffness in an asymptomatic population. J Hum Hypertens (2005) 1.19
Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion in 16 patients. Ann Intern Med (1977) 1.19
Hemodynamic effects of orally administered isosorbide dinitrate in patients with congestive heart failure. Circulation (1974) 1.17
In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain (1999) 1.17
The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation (1993) 1.16
Right ventricular infarction revisited. Am J Cardiol (1979) 1.15
Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol (1997) 1.15
Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation (1993) 1.14
Hemodynamic effect of dobutamine in patients with severe heart failure. Am J Cardiol (1975) 1.14
Comparative hemodynamic effects of chewable isosorbide dinitrate and nitroglycerin in patients with congestive heart failure. Circulation (1975) 1.14
Ultrasound evaluation of systolic anterior septal motion in patients with and without right ventricular volume overload. Circulation (1974) 1.13
TNF-alpha and heart failure. The difference between proof of principle and hypothesis testing. Circulation (1999) 1.13
Cardiac and peripheral vascular effects of digitalis in clinical cardiogenic shock. Am Heart J (1969) 1.13
Poisoning from ingestion of a stramonium-belladonna mixture: flower power gone sour. JAMA (1968) 1.12